Is Quizartinib a chemotherapy drug?

Quizartinib, trade name: Vanflyta, is an innovative targeted therapy drug, not a chemotherapy drug in the traditional sense. It has been approved for use with chemotherapy drugs as a first-line treatment option for adult patients with acute myeloid leukemia (AML) whose FLT3gene mutation is "FLT3-ITD". Patients received quizartinib by mouth once daily for two weeks at approximately the same time during each chemotherapy cycle as part of their treatment.

Quizatinib is unique in its targeting nature. It targets a specific genetic mutation called FLT3-ITD, which is common in patients with AML and is often associated with a poor prognosis for the disease. By inhibiting the activity of FLT3 kinase, Quizartinib can block the cell signaling pathway driven by the FLT3-ITD mutation, thereby effectively inhibiting the proliferation and survival of leukemia cells.

Compared with traditional chemotherapy drugs, quizartinib has higher selectivity and lower off-target toxicity. This means it can target cancer cells more precisely while causing less damage to the patient's normal cells. Therefore, the combined use of quizartinib and chemotherapy drugs aims to improve the therapeutic effect while reducing the side effects of treatment and the impact on patients' quality of life.

However, it is worth noting that although quizartinib is a targeted therapy, it still needs to be used under the guidance of a professional doctor. Doctors will develop a personalized treatment plan based on the patient's specific condition, physical condition and tolerance, and closely monitor the patient's treatment response and possible side effects. In addition, due to the combined use of quizartinib and chemotherapy drugs, patients also need to be aware of drug-drug interactions and potential accumulation of toxicities.

In general, quizartinib is an effective targeted therapy for FLT3-ITDpositiveAML patients. Its combination with chemotherapy drugs provides patients with new treatment options and hope. However, it is necessary to strictly follow medical instructions during use and closely monitor the patient's treatment response and physical condition.

xa0

Reference: https://www.gov.uk/government/news/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer